Kirsten H. Ohler
Research Subjects
Research Interests
Kirsten H. Ohler has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Andrew Posen
University of Illinois Hospital and Health Sciences System (UI Health), Chicago, IL, USA
2 shared publications Alma R. Bicknese
Children's Hospital University of Illinois, University of Illinois Hospital & Health Sciences System, Chicago ; Department of Pediatrics, College of Medicine, University of Illinois, Chicago
1 shared publication- Braxton M Snuffer
UIC Retzky College of Pharmacy. Department of Pharmacy Practice. 833 S Wood St. 164, MC 886. Chicago, Illinois. 60612
1 shared publication - Brianna McQuade Hudak
Department of Pharmacy Practice, University of Illinois Chicago Retzky College of Pharmacy
1 shared publication Christian J Phillips
UIC Retzky College of Pharmacy. Department of Pharmacy Practice. 833 S Wood St. 164, MC 886. Chicago, Illinois. 60612
1 shared publicationDeborah S. Raithel
Pediatric Pharmacy Resident, Department of Pharmacy Practice, College of Pharmacy, University of Illinois, Chicago, currently at Comer Children's Hospital, The University of Chicago Medicine, Chicago
1 shared publication
Latest Publications
- 4 July 2026
- Published by Elsevier in American Journal of Pharmaceutical Education
- Vol. 90 (9) , 102043
Responding to: July 1 Licensure Pressure for Pharmacy Residents — Why Early Licensure Matters
- 4 July 2026
- Published by Elsevier in American Journal of Pharmaceutical Education
- Vol. 90 (9) , 102043
Responding to: July 1 Licensure Pressure for Pharmacy Residents — Why Early Licensure Matters
- 22 February 2026
- Published by Wiley in JACCP: Journal of the American College of Clinical Pharmacy
- Vol. 9 (3) , e70191
Impact of an In‐House Resident Clinical Pharmacist On‐Call Program on Resident Physician Training: A Cross‐Sectional Survey
Background: Interdisciplinary collaboration is a core component of residency training. At the University of Illinois Hospital & Health Sciences System (UI Health), a 24‐h in‐hospital Doctor of Pharmacy (Pharm.D.) resident on‐call program provides real‐time clinical support to health care teams. Although primarily patient care‐directed, these interactions offer a platform for interprofessional learning. The educational value of pharmacy resident involvement in training physician residents remains underexplored. Methods: A prospective cross‐sectional survey was conducted in March 2025, targeting UI Health inpatient physician residents across specialties. Eligible residents received email invitations to complete an anonymous Qualtrics survey of their perceptions about the Pharm.D. resident on‐call program. Quantitative data were analyzed using descriptive statistics; qualitative feedback underwent thematic analysis. The primary outcome was the percentage of residents reporting a positive impact on their training. Secondary outcomes included satisfaction by specialty, areas of clinical knowledge growth, perceived accessibility, self‐reported confidence, and reasons for lack of interaction with the Pharm.D. on‐call. Results: Of 557 residents, 97 responded (17% response rate). Among the 87 who interacted with a pharmacy resident, 93.0% reported a positive training impact. These interactions were associated with improved pharmaceutical knowledge (89.7%), particularly in dosing adjustments, anticoagulation management, drug interactions, and contraindications. Residents reported that Pharm.D. on‐call collaboration enhanced their confidence in patient care (92.0%) and contributed to feeling more prepared for independent practice (70.1%). Qualitative responses highlighted physician residents' appreciation for the on‐call program's contributions to medication safety, with conveyed interest in expanding the program's availability and educational opportunities. Responding physician residents also emphasized the need for increased awareness of the program across underutilizing specialties. Conclusion: The Pharm.D. resident on‐call program was well‐received and perceived to enhance physician resident education. Future efforts should focus on increasing program visibility, targeted specialty outreach, and enhancing pharmacists' responsibility and integration in physician residency training and education.
- 22 February 2026
- Published by Wiley in JACCP: Journal of the American College of Clinical Pharmacy
- Vol. 9 (3) , e70191
Impact of an In‐House Resident Clinical Pharmacist On‐Call Program on Resident Physician Training: A Cross‐Sectional Survey
Background: Interdisciplinary collaboration is a core component of residency training. At the University of Illinois Hospital & Health Sciences System (UI Health), a 24‐h in‐hospital Doctor of Pharmacy (Pharm.D.) resident on‐call program provides real‐time clinical support to health care teams. Although primarily patient care‐directed, these interactions offer a platform for interprofessional learning. The educational value of pharmacy resident involvement in training physician residents remains underexplored. Methods: A prospective cross‐sectional survey was conducted in March 2025, targeting UI Health inpatient physician residents across specialties. Eligible residents received email invitations to complete an anonymous Qualtrics survey of their perceptions about the Pharm.D. resident on‐call program. Quantitative data were analyzed using descriptive statistics; qualitative feedback underwent thematic analysis. The primary outcome was the percentage of residents reporting a positive impact on their training. Secondary outcomes included satisfaction by specialty, areas of clinical knowledge growth, perceived accessibility, self‐reported confidence, and reasons for lack of interaction with the Pharm.D. on‐call. Results: Of 557 residents, 97 responded (17% response rate). Among the 87 who interacted with a pharmacy resident, 93.0% reported a positive training impact. These interactions were associated with improved pharmaceutical knowledge (89.7%), particularly in dosing adjustments, anticoagulation management, drug interactions, and contraindications. Residents reported that Pharm.D. on‐call collaboration enhanced their confidence in patient care (92.0%) and contributed to feeling more prepared for independent practice (70.1%). Qualitative responses highlighted physician residents' appreciation for the on‐call program's contributions to medication safety, with conveyed interest in expanding the program's availability and educational opportunities. Responding physician residents also emphasized the need for increased awareness of the program across underutilizing specialties. Conclusion: The Pharm.D. resident on‐call program was well‐received and perceived to enhance physician resident education. Future efforts should focus on increasing program visibility, targeted specialty outreach, and enhancing pharmacists' responsibility and integration in physician residency training and education.
- 5 June 2025
- Published by Wiley in JACCP: Journal of the American College of Clinical Pharmacy
- Vol. 8 (7) , 530-532
Pharmacy residency leave time: One size does not fit all
- 5 June 2025
- Published by Wiley in JACCP: Journal of the American College of Clinical Pharmacy
- Vol. 8 (7) , 530-532
Pharmacy residency leave time: One size does not fit all
- 9 July 2024
- Published by Wiley in JACCP: Journal of the American College of Clinical Pharmacy
- Vol. 7 (7) , 678
Comment on “Factors associated with attaining a pharmacy residency interview: A scoping review”
- 9 July 2024
- Published by Wiley in JACCP: Journal of the American College of Clinical Pharmacy
- Vol. 7 (7) , 678
Comment on “Factors associated with attaining a pharmacy residency interview: A scoping review”
- 7 June 2023
- Published by Wiley in JACCP: Journal of the American College of Clinical Pharmacy
- Vol. 6 (6) , 654
Comment on “Evaluation of pharmacy residency recruitment and interview processes during the COVID‐19 pandemic”
- 7 June 2023
- Published by Wiley in JACCP: Journal of the American College of Clinical Pharmacy
- Vol. 6 (6) , 654
Comment on “Evaluation of pharmacy residency recruitment and interview processes during the COVID‐19 pandemic”
- 18 October 2017
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 37 (11) , e122-e123
The Effect of Morphine Dosing on Length of Stay in Neonatal Abstinence Syndrome – An Alternative Viewpoint
- 18 October 2017
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 37 (11) , e122-e123
The Effect of Morphine Dosing on Length of Stay in Neonatal Abstinence Syndrome – An Alternative Viewpoint
- 1 January 2015
- Published by The Pediatric Pharmacy Association in The Journal of Pediatric Pharmacology and Therapeutics
- Vol. 20 (4) , 335-340
Morphine: An Effective Abortive Therapy for Pediatric Paroxysmal Sympathetic Hyperactivity After Hypoxic Brain Injury
Paroxysmal sympathetic hyperactivity (PSH) is a life-threatening condition characterized by hyperadrenergic activity and autonomic dysfunction. Also termed autonomic storms, PSH can occur after a variety of cerebral insults, most commonly traumatic brain injury. Limited pediatric literature is available, especially in patients with brain injury from hypoxia. No consensus exists for the terminology, diagnostic criteria, or treatment algorithm for PSH. Thus, the optimal management, including medication selection and dosing, remains unclear. We present the detailed treatment of a 9-year-old, African American male with hypoxic brain injury after pulseless arrest following status asthmaticus, who subsequently developed PSH. The patient began to experience episodes of tachycardia, hypertension, tachypnea, diaphoresis, rigidity, and dystonic posturing on hospital day 5. After ruling out other potential causes, a diagnosis of PSH was made. Episodes of PSH failed to respond to lorazepam or labetalol but were aborted successfully with morphine. Management of PSH after hypoxic brain injury required medications for acute treatment as well as for prevention of PSH. Morphine was found to be highly effective and safe for aborting the autonomic crises. Other agents more commonly described in the literature did not result in an adequate response and were associated with significant adverse effects. A combination of clonazepam, baclofen, and either propranolol or clonidine aided in reducing the frequency of episodes of PSH. We suggest using morphine for aborting severe episodes of PSH that do not respond to antihypertensive agents or benzodiazepines.
- 1 January 2015
- Published by The Pediatric Pharmacy Association in The Journal of Pediatric Pharmacology and Therapeutics
- Vol. 20 (4) , 335-340
Morphine: An Effective Abortive Therapy for Pediatric Paroxysmal Sympathetic Hyperactivity After Hypoxic Brain Injury
Paroxysmal sympathetic hyperactivity (PSH) is a life-threatening condition characterized by hyperadrenergic activity and autonomic dysfunction. Also termed autonomic storms, PSH can occur after a variety of cerebral insults, most commonly traumatic brain injury. Limited pediatric literature is available, especially in patients with brain injury from hypoxia. No consensus exists for the terminology, diagnostic criteria, or treatment algorithm for PSH. Thus, the optimal management, including medication selection and dosing, remains unclear. We present the detailed treatment of a 9-year-old, African American male with hypoxic brain injury after pulseless arrest following status asthmaticus, who subsequently developed PSH. The patient began to experience episodes of tachycardia, hypertension, tachypnea, diaphoresis, rigidity, and dystonic posturing on hospital day 5. After ruling out other potential causes, a diagnosis of PSH was made. Episodes of PSH failed to respond to lorazepam or labetalol but were aborted successfully with morphine. Management of PSH after hypoxic brain injury required medications for acute treatment as well as for prevention of PSH. Morphine was found to be highly effective and safe for aborting the autonomic crises. Other agents more commonly described in the literature did not result in an adequate response and were associated with significant adverse effects. A combination of clonazepam, baclofen, and either propranolol or clonidine aided in reducing the frequency of episodes of PSH. We suggest using morphine for aborting severe episodes of PSH that do not respond to antihypertensive agents or benzodiazepines.
- 1 January 2012
- Published by AACN Publishing in AACN Advanced Critical Care
- Vol. 23 (4) , 398-412
Pharmacotherapy of Pediatric Advanced Life Support and Toxicological Emergencies
Guidelines for pediatric advanced life support have been available for nearly a quarter of a century. Recommendations for the pharmacological management of pediatric cardiac arrest have changed over these years. Several important differences have been observed between adult advanced cardiac life support and pediatric advanced life support that must be recognized when children require resuscitation, such as the cause of the arrest, age-specific monitoring parameters, weight-based medication dosing, and obstacles in obtaining venous access. To make matters more complicated, differences also exist across neonatal and pediatric age spectrums. In addition, some toxicological emergencies commonly occurring in children require pharmacological management with agents that have a unique mechanism of action for cardiac support.
- 1 January 2012
- Published by AACN Publishing in AACN Advanced Critical Care
- Vol. 23 (4) , 398-412
Pharmacotherapy of Pediatric Advanced Life Support and Toxicological Emergencies
Guidelines for pediatric advanced life support have been available for nearly a quarter of a century. Recommendations for the pharmacological management of pediatric cardiac arrest have changed over these years. Several important differences have been observed between adult advanced cardiac life support and pediatric advanced life support that must be recognized when children require resuscitation, such as the cause of the arrest, age-specific monitoring parameters, weight-based medication dosing, and obstacles in obtaining venous access. To make matters more complicated, differences also exist across neonatal and pediatric age spectrums. In addition, some toxicological emergencies commonly occurring in children require pharmacological management with agents that have a unique mechanism of action for cardiac support.